Bullzeye FinancialConcord Biotech Ltd.
NSE: CONCORDBIO · Healthcare
₹1,392.70
as of 28 Sep 2026
AI verdict · 28 Sep 2026
Bullish
68% confidence
Confirmed Q1 earnings growth of 33% YoY and clean FDA inspection provide fundamental support for the uptrend, though weak volume and…
Strongest bull point
Q1 FY27 net profit surged 32.84% YoY to ₹58.53 crore with 26.23% revenue growth, validating the 40.77% 6-month stock outperformance against NIFTY and demonstrating real earnings momentum.
Strongest bear point
12-month underperformance of 2.48pp versus NIFTY, neutral RSI, and volume 24% below average suggest the rally is mean-reversion with weak institutional conviction, not durable recovery.
Technical Forecast · next 10 trading days
Expected
₹1,391.96 -0.1%
Range
₹1,389.02 – ₹1,404.61
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
Every call on CONCORDBIO, misses included
-
Bullish 28 Sep 2026 → now Scores 28 Oct 2026₹1,392.70 → ₹1,392.70 0.0%
Our accuracy
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →More Healthcare